SCHEMBL454129

SCHEMBL454129

O=[N+]([O-])c1ccccc1S(=O)(=O)NCCO

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.67
KMT2A Q03164 3/20 0.64
MEN1 O00255 2/20 0.64
CA1 P00915 1/20 0.64
CA2 P00918 1/20 0.64
MMP1 P03956 1/20 0.64
MMP2 P08253 1/20 0.64
MMP9 P14780 1/20 0.64
MMP8 P22894 1/20 0.64
MMP13 P45452 1/20 0.64
CYP19A1 P11511 1/20 0.61
LMNA P02545 1/20 0.58
CA12 O43570 1/20 0.58
HTT P42858 1/20 0.57
F2 P00734 1/20 0.55
PRSS1 P07477 1/20 0.55
PRSS2 P07478 1/20 0.55
PRSS3 P35030 1/20 0.55
THRB P10828 1/20 0.55
NPY5R Q15761 3/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30649118 0.90 KMT2A (0.71) ALDH1A1KMT2AMEN1CA1CA2
SCHEMBL4389696 0.90 KMT2A (0.71) ALDH1A1KMT2AMEN1CA1CA2
SCHEMBL18319951 0.90 KMT2A (0.60) ALDH1A1KMT2AMEN1CA1CA2
SCHEMBL31284709 0.87 KMT2A (0.68) ALDH1A1KMT2AMEN1CA1CA2
SCHEMBL29571128 0.87 KMT2A (0.68) ALDH1A1KMT2AMEN1CA1CA2
SCHEMBL27006685 0.87 KMT2A (0.68) ALDH1A1KMT2AMEN1CA1CA2
SCHEMBL3540913 0.86 KMT2A (0.66) ALDH1A1KMT2AMEN1CA1CA2
SCHEMBL4362943 0.86 KMT2A (0.66) ALDH1A1KMT2AMEN1CA1CA2
SCHEMBL1029644 0.86 KMT2A (0.66) ALDH1A1KMT2AMEN1CA1CA2
SCHEMBL29570715 0.86 KMT2A (0.66) ALDH1A1KMT2AMEN1CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119233829-A Pharmaceutical composition for preventing, inhibiting or treating symptoms associated with pseudoallergy 学校法人高崎健康福祉大学 2024-12-31 CN claimed
CN-118176003-A Medicaments comprising P2X4 receptor antagonists for the prevention or treatment of nociceptive pain and/or visceral pain 日本化学药品株式会社 2024-06-11 CN claimed
CN-118019551-A Preventive or therapeutic agent for respiratory diseases 日本化学药品株式会社 2024-05-10 CN claimed
CN-115942938-A Medicine for preventing or treating irritable bowel syndrome or inflammatory bowel disease 比萨大学 2023-04-07 CN claimed
WO-2024259171-A9 KEAP1 INHIBITORS AND USES THEREOF VIVIDION THERAPEUTICS, INC. (US) 2025-01-23 WO disclosed
US-20250011291-A1 KEAP1 INHIBITORS AND USES THEREOF VIVIDION THERAPEUTICS, INC. 2025-01-09 US disclosed
CN-119233829-A Pharmaceutical composition for preventing, inhibiting or treating symptoms associated with pseudoallergy 学校法人高崎健康福祉大学 2024-12-31 CN disclosed
WO-2024259171-A2 KEAP1 INHIBITORS AND USES THEREOF VIVIDION THERAPEUTICS, INC. (US) 2024-12-19 WO disclosed
CN-118176003-A Medicaments comprising P2X4 receptor antagonists for the prevention or treatment of nociceptive pain and/or visceral pain 日本化学药品株式会社 2024-06-11 CN disclosed
CN-118019551-A Preventive or therapeutic agent for respiratory diseases 日本化学药品株式会社 2024-05-10 CN disclosed
CN-115942938-A Medicine for preventing or treating irritable bowel syndrome or inflammatory bowel disease 比萨大学 2023-04-07 CN disclosed
US-20190082845-A1 CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS INCURON INC (US) 2019-03-21 US disclosed
CN-1777423-A Chemokine receptor binding heterocyclic compounds with enhanced efficacy ANORMED INC (CA) 2006-05-24 CN disclosed
EP-1642880-A1 HSP90 FAMILY PROTEIN INHIBITORS KYOWA HAKKO KOGYO CO., LTD. (JP) 2006-04-05 EP disclosed
EP-1615633-A2 CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY ANORMED INC. (CA) 2006-01-18 EP disclosed
US-20050154201-A1 Methods of making 2,6-diaryl piperidine derivatives ANORMED CORPORATION (CA) 2005-07-14 US disclosed
US-20050059702-A1 Chemokine receptor binding heterocyclic compounds with enhanced efficacy ANORMED CORPORATION (CA) 2005-03-17 US disclosed
WO-2004093817-A2 CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY ANORMED INC. (CA) 2004-11-04 WO disclosed
US-6716961-B2 Chiral peptide nucleic acids with a N-aminoethyl-d-proline backbone ISIS INNOVATION LIMITED (GB) 2004-04-06 US disclosed
US-20030162699-A1 Chiral peptide nucleic acids with a n-aminoethyl-d-proline backbone ISIS INNOVATION LIMITED (GB) 2003-08-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050154201-A1 Methods of making 2,6-diaryl piperidine derivatives ALDH7A1, DPYD, ALDH1A1 ALDH1A1 3/4885KMT2A 1667/4885MEN1 2676/4885
US-20030162699-A1 Chiral peptide nucleic acids with a n-aminoethyl-d-proline backbone POLL, HNRNPL, RNGTT ALDH1A1 4356/4885KMT2A 2081/4885MEN1 3219/4885
US-20250011291-A1 KEAP1 INHIBITORS AND USES THEREOF KEAP1, NFE2L2, NQO1 ALDH1A1 565/4885KMT2A 1356/4885MEN1 3793/4885
US-20050059702-A1 Chemokine receptor binding heterocyclic compounds with enhanced efficacy CXCR4, CXCR1, CCR5 ALDH1A1 290/4885KMT2A 2901/4885MEN1 4295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.